764 related articles for article (PubMed ID: 11817593)
1. Association of baseline levels of urinary glucosyl-galactosyl-pyridinoline and type II collagen C-telopeptide with progression of joint destruction in patients with early rheumatoid arthritis.
Garnero P; Gineyts E; Christgau S; Finck B; Delmas PD
Arthritis Rheum; 2002 Jan; 46(1):21-30. PubMed ID: 11817593
[TBL] [Abstract][Full Text] [Related]
2. Urinary type II collagen helical peptide (HELIX-II) as a new biochemical marker of cartilage degradation in patients with osteoarthritis and rheumatoid arthritis.
Charni N; Juillet F; Garnero P
Arthritis Rheum; 2005 Apr; 52(4):1081-90. PubMed ID: 15818703
[TBL] [Abstract][Full Text] [Related]
3. Effects of infliximab therapy on biological markers of synovium activity and cartilage breakdown in patients with rheumatoid arthritis.
Marotte H; Gineyts E; Miossec P; Delmas PD
Ann Rheum Dis; 2009 Jul; 68(7):1197-200. PubMed ID: 18713784
[TBL] [Abstract][Full Text] [Related]
4. Uncoupling of type II collagen synthesis and degradation predicts progression of joint damage in patients with knee osteoarthritis.
Garnero P; Ayral X; Rousseau JC; Christgau S; Sandell LJ; Dougados M; Delmas PD
Arthritis Rheum; 2002 Oct; 46(10):2613-24. PubMed ID: 12384919
[TBL] [Abstract][Full Text] [Related]
5. Cross sectional evaluation of biochemical markers of bone, cartilage, and synovial tissue metabolism in patients with knee osteoarthritis: relations with disease activity and joint damage.
Garnero P; Piperno M; Gineyts E; Christgau S; Delmas PD; Vignon E
Ann Rheum Dis; 2001 Jun; 60(6):619-26. PubMed ID: 11350852
[TBL] [Abstract][Full Text] [Related]
6. Association of baseline levels of markers of bone and cartilage degradation with long-term progression of joint damage in patients with early rheumatoid arthritis: the COBRA study.
Garnero P; Landewé R; Boers M; Verhoeven A; Van Der Linden S; Christgau S; Van Der Heijde D; Boonen A; Geusens P
Arthritis Rheum; 2002 Nov; 46(11):2847-56. PubMed ID: 12428224
[TBL] [Abstract][Full Text] [Related]
7. The combination of the biomarkers urinary C-terminal telopeptide of type II collagen, serum cartilage oligomeric matrix protein, and serum chondroitin sulfate 846 reflects cartilage damage in hemophilic arthropathy.
Jansen NW; Roosendaal G; Lundin B; Heijnen L; Mauser-Bunschoten E; Bijlsma JW; Theobald M; Lafeber FP
Arthritis Rheum; 2009 Jan; 60(1):290-8. PubMed ID: 19116938
[TBL] [Abstract][Full Text] [Related]
8. Long-term effects of infliximab on bone and cartilage turnover markers in patients with rheumatoid arthritis.
Chopin F; Garnero P; le Henanff A; Debiais F; Daragon A; Roux C; Sany J; Wendling D; Zarnitsky C; Ravaud P; Thomas T
Ann Rheum Dis; 2008 Mar; 67(3):353-7. PubMed ID: 17644538
[TBL] [Abstract][Full Text] [Related]
9. Serum matrix metalloproteinase 3 levels during treatment with sulfasalazine or combination of methotrexate and sulfasalazine in patients with early rheumatoid arthritis.
Posthumus MD; Limburg PC; Westra J; van Leeuwen MA; van Rijswijk MH
J Rheumatol; 2002 May; 29(5):883-9. PubMed ID: 12022344
[TBL] [Abstract][Full Text] [Related]
10. Effects of ibuprofen on molecular markers of cartilage and synovium turnover in patients with knee osteoarthritis.
Gineyts E; Mo JA; Ko A; Henriksen DB; Curtis SP; Gertz BJ; Garnero P; Delmas PD
Ann Rheum Dis; 2004 Jul; 63(7):857-61. PubMed ID: 15194584
[TBL] [Abstract][Full Text] [Related]
11. Circulating levels of matrix metalloproteinases MMP-3 and MMP-1, tissue inhibitor of metalloproteinases 1 (TIMP-1), and MMP-1/TIMP-1 complex in rheumatic disease. Correlation with clinical activity of rheumatoid arthritis versus other surrogate markers.
Keyszer G; Lambiri I; Nagel R; Keysser C; Keysser M; Gromnica-Ihle E; Franz J; Burmester GR; Jung K
J Rheumatol; 1999 Feb; 26(2):251-8. PubMed ID: 9972954
[TBL] [Abstract][Full Text] [Related]
12. Biomarkers predict radiographic progression in early rheumatoid arthritis and perform well compared with traditional markers.
Young-Min S; Cawston T; Marshall N; Coady D; Christgau S; Saxne T; Robins S; Griffiths I
Arthritis Rheum; 2007 Oct; 56(10):3236-47. PubMed ID: 17907159
[TBL] [Abstract][Full Text] [Related]
13. Etanercept exerts beneficial effects on articular cartilage biomarkers of degradation and turnover in patients with ankylosing spondylitis.
Maksymowych WP; Poole AR; Hiebert L; Webb A; Ionescu M; Lobanok T; King L; Davis JC
J Rheumatol; 2005 Oct; 32(10):1911-7. PubMed ID: 16206346
[TBL] [Abstract][Full Text] [Related]
14. Combination drug strategy in recent-onset rheumatoid arthritis suppresses collagen I degradation and is associated with retardation of radiological progression.
Hakala M; Risteli J; Aman S; Kautiainen H; Korpela M; Hannonen P; Leirisalo-Repo M; Laasonen L; Paimela L; Möttönen T;
Scand J Rheumatol; 2008; 37(2):90-3. PubMed ID: 18415764
[TBL] [Abstract][Full Text] [Related]
15. Turnover of type II collagen and aggrecan in cartilage matrix at the onset of inflammatory arthritis in humans: relationship to mediators of systemic and local inflammation.
Fraser A; Fearon U; Billinghurst RC; Ionescu M; Reece R; Barwick T; Emery P; Poole AR; Veale DJ
Arthritis Rheum; 2003 Nov; 48(11):3085-95. PubMed ID: 14613270
[TBL] [Abstract][Full Text] [Related]
16. A combination of biochemical markers of cartilage and bone turnover, radiographic damage and body mass index to predict the progression of joint destruction in patients with rheumatoid arthritis treated with disease-modifying anti-rheumatic drugs.
Hashimoto J; Garnero P; van der Heijde D; Miyasaka N; Yamamoto K; Kawai S; Takeuchi T; Yoshikawa H; Nishimoto N
Mod Rheumatol; 2009; 19(3):273-82. PubMed ID: 19452245
[TBL] [Abstract][Full Text] [Related]
17. High serum cartilage oligomeric matrix protein determines the subset of patients with early-stage rheumatoid arthritis with high serum C-reactive protein, matrix metalloproteinase-3, and MRI-proven bone erosion.
Fujikawa K; Kawakami A; Tamai M; Uetani M; Takao S; Arima K; Iwamoto N; Aramaki T; Kawashiri S; Ichinose K; Kamachi M; Nakamura H; Origuchi T; Ida H; Aoyagi K; Eguchi K
J Rheumatol; 2009 Jun; 36(6):1126-9. PubMed ID: 19447929
[TBL] [Abstract][Full Text] [Related]
18. Markers for type II collagen breakdown predict the effect of disease-modifying treatment on long-term radiographic progression in patients with rheumatoid arthritis.
Landewé R; Geusens P; Boers M; van der Heijde D; Lems W; te Koppele J; van der Linden S; Garnero P
Arthritis Rheum; 2004 May; 50(5):1390-9. PubMed ID: 15146408
[TBL] [Abstract][Full Text] [Related]
19. Urinary excretion of glucosyl-galactosyl pyridinoline: a specific biochemical marker of synovium degradation.
Gineyts E; Garnero P; Delmas PD
Rheumatology (Oxford); 2001 Mar; 40(3):315-23. PubMed ID: 11285380
[TBL] [Abstract][Full Text] [Related]
20. Changes of clinical response and bone biochemical markers in patients with ankylosing spondylitis taking etanercept.
Woo JH; Lee HJ; Sung IH; Kim TH
J Rheumatol; 2007 Aug; 34(8):1753-9. PubMed ID: 17610317
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
